• MDM1 Overexpression Drives Apoptosis and Chemoradiotherapy S

  2026-05-09

  This study identifies MDM1 as a key molecular regulator enhancing p53-mediated apoptosis and chemoradiotherapy sensitivity in colorectal cancer cells. The findings suggest MDM1 as a potential predictive biomarker and therapeutic lever for overcoming treatment resistance.

• N1-Methyl-Pseudouridine-5'-Triphosphate: Mechanism & Evidenc

  2026-05-09

  N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP) is a modified nucleoside triphosphate that enhances RNA stability and translational efficiency. Its use in in vitro transcription with modified nucleotides is foundational for mRNA vaccine development and RNA translation mechanism research. Peer-reviewed evidence and workflow guidelines establish its pivotal role in next-generation RNA synthesis.

• Synthetic Lethality of Dinaciclib in VHL-Deficient Renal Can

  2026-05-08

  This study identifies Dinaciclib, a cyclin-dependent kinase inhibitor, as a selective therapeutic agent for clear cell renal cell carcinoma (CC-RCC) with VHL deficiency. By exploiting synthetic lethality, Dinaciclib demonstrates potent anti-tumor effects both in vitro and in vivo, advancing targeted strategies for hard-to-treat kidney cancers.

• PD 0332991 (Palbociclib) HCl: Reliable CDK4/6 Inhibition in

  2026-05-07

  This article grounds the practical application of PD 0332991 (Palbociclib) HCl (SKU A8316) in real-world cell assay challenges, emphasizing validated protocols and data-backed performance for cell viability and proliferation studies. Drawing on published evidence and direct experience, it guides researchers in optimizing workflows for robust, reproducible results with this selective CDK4/6 inhibitor.

• Lisinopril Dihydrate: Molecular Selectivity and Assay Precis

  2026-05-07

  Explore the molecular selectivity of Lisinopril dihydrate, a potent ACE inhibitor, and how its distinct assay properties advance hypertension and heart failure research. This article uncovers mechanistic insights and practical assay guidance for rigorous biomedical studies.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Test

  2026-05-06

  This study introduces a patient-derived gastric cancer assembloid system that integrates tumor organoids with autologous stromal cell subpopulations, more accurately modeling the tumor microenvironment. The platform demonstrates improved prediction of drug responses and highlights the importance of including stromal diversity in preclinical research.

• Morning Training Enhances Endurance Adaptation in Mice

  2026-05-06

  Hesketh et al. demonstrate that morning endurance training (ZT13) in mice leads to greater improvements in performance and muscle adaptation compared to afternoon training, despite lower training volumes. These findings underscore the importance of exercise timing in optimizing endurance adaptation and inform experimental protocols for metabolic research.

• Tolazoline: Mechanistic Leverage for Translational Pathway R

  2026-05-05

  This article provides a systems-level, mechanistic, and strategic perspective on Tolazoline—an α2-adrenergic receptor antagonist and ATP-sensitive potassium channel blocker—highlighting its unique value for translational researchers in islet function and airway smooth muscle studies. Integrating recent methodological advances and competitive benchmarks, we offer actionable guidance for assay optimization, protocol selection, and future direction, with a comparative focus on APExBIO’s Tolazoline (SKU A8991).

• Tolazoline (SKU A8991): Robust Solutions for In Vitro Assays

  2026-05-05

  This article delivers a scenario-driven, evidence-based guide for biomedical researchers using Tolazoline (SKU A8991) in cell viability, islet function, and airway smooth muscle assays. By addressing real workflow challenges and citing quantitative literature, it demonstrates how Tolazoline enhances reproducibility and mechanistic clarity across key research applications.

• Ertugliflozin Mitigates Brain Insulin Disruption in Alzheime

  2026-05-04

  The referenced study demonstrates that the SGLT2 inhibitor ertugliflozin effectively counteracts brain insulin signaling impairment and tau hyperphosphorylation in a rat model of Alzheimer’s disease. These results highlight the therapeutic potential of metabolic pathway modulation in neurodegenerative disease, while also informing future strategies for targeting insulin resistance in the brain.

• U0126 as a MEK1/2 Inhibitor: Applied Workflows in Cancer Bio

  2026-05-04

  U0126 stands out as a potent MEK1/2 inhibitor for dissecting the MAPK/ERK pathway, offering researchers precision in probing cell signaling and resistance mechanisms. This article bridges protocol optimization, real-world troubleshooting, and emerging insights from reference studies to advance cancer biology and autophagy research.

• AI-Derived Prognostic Signature Advances HCC Precision Oncol

  2026-05-03

  This multi-center study presents a consensus AI-driven prognostic signature (CAIPS) for hepatocellular carcinoma (HCC), integrating ten machine learning algorithms across large patient cohorts. The CAIPS model demonstrates superior prognostic accuracy and identifies actionable therapeutic targets, offering a robust framework for risk stratification and personalized therapy in HCC.

• PKM2 Inhibitor (Compound 3k): Applied Workflows & Troublesho

  2026-05-02

  PKM2 inhibitor (compound 3k) unlocks targeted disruption of tumor glycolysis and immune cell metabolic reprogramming, outperforming conventional agents in selectivity and in vivo tolerability. This guide translates the latest evidence into actionable protocols, troubleshooting, and research optimizations for cancer and inflammation studies.

• FH1 Small Molecule: Enhancing iPS-Derived Hepatocyte Maturat

  2026-05-02

  FH1 (Catalog No. B3700) is a small molecule that enhances the functional maturation of hepatocyte-like cells derived from induced pluripotent stem cells (iPSCs). It doubles albumin secretion and boosts CYP3A4 expression, facilitating advanced in vitro liver research and transplantation workflows.

• SMYD2 Inhibition by AZ505 Mitigates Cisplatin-Induced Renal

  2026-05-01

  This study demonstrates that pharmacological inhibition of SMYD2 using AZ505 alleviates renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease (CKD) model. The findings clarify the role of SMYD2-mediated histone methylation in CKD progression and offer mechanistic insight into potential therapeutic strategies targeting epigenetic regulation.

455 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page